To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 January 2019 to Question 207185 on Cannabis: Medical Treatments, whether data on prescriptions of cannabis-based medicinal products will include (a) the type of product prescribed, (b) the indication that product was prescribed for and (c) the number of those such prescriptions by NHS clinical commissioning group area.
21 March 2019
NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. Scotland, Wales and Northern Ireland are in the process of setting up similar systems.
In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector. We expect this data to be available by end of March 2019.